Casdin Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Casdin Capital’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-375,000	Closed	-$2.44M	–	37
2018 Q3	$2.44M	Hold	375,000	–	–	0.3%	36
2018 Q2	$2.87M	Sell	375,000 -260,000	-41%	-$3.75M	0.4%	31
2018 Q1	$14.2M	Buy	635,000 +160,000	+34%	+$3.55M	2.5%	18
2017 Q4	$6.06M	Buy	475,000 +75,175	+19%	+$1.11M	1.47%	20
2017 Q3	$6.23M	Buy	399,825 +239,825	+150%	+$3.39M	1.76%	20
2017 Q2	$2.25M	Buy	160,000 +30,000	+23%	+$642K	0.83%	29
2017 Q1	$2.86M	Buy	+130,000	New	+$2.75M	1.69%	23

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Casdin Capital's JNCE Position: Q4 2018 in Review

Casdin Capital sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2018, closing a stake of 375,000 shares — an estimated $2.44M sold.

Casdin Capital first reported a position in JNCE in Q1 2017 and held it in 7 quarters. The position peaked at $14.2M in Q1 2018. 84 funds tracked by Wall St. Rank hold JNCE as of Q4 2018.

Casdin Capital reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Casdin Capital sold 375,000 Jounce Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $2.44M.
Casdin Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 7 quarters.
Casdin Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $14.2M in Q1 2018.
84 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Casdin Capital's 13F filing for Q4 2018, filed 13 Feb 2019.